Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
human umbilical cord mesenchymal stem cell-derived exosomes
- Development stage
- Phase 2
- Lead developer
- Xijing Hospital
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Intranasal, Ophthalmic, Intralesional, Inhalation, Parenteral
01
Overview
Human umbilical cord mesenchymal stem cell-derived exosomes (hUC-MSC-Exos) are nanosized extracellular vesicles, typically ranging from 30 to 200 nm in diameter, secreted by mesenchymal stem cells harvested from human umbilical cord tissue. As a cell-free therapeutic platform, these exosomes carry a complex cargo of bioactive molecules, including microRNAs (e.g., miR-129-5p, miR-19a), long non-coding RNAs (e.g., lncRNA-9969), and proteins (e.g., TGF-beta 1), which mediate intercellular communication and tissue regeneration. The therapeutic mechanism involves the modulation of multiple signaling pathways, such as the activation of the SIRT1-FXR axis to inhibit NLRP3 inflammasome activity in macrophages and the targeting of ACSL4 to suppress ferroptosis and lipid peroxidation. hUC-MSC-Exos are currently being investigated in numerous clinical trials for diverse indications, including inflammatory bowel disease, autoimmune encephalitis, vitiligo, dry eye disease, and neurodegenerative disorders, offering a potential alternative to stem cell transplantation with reduced risks of immunogenicity and tumorigenicity.
- Other names
- 脐带间充质干细胞外泌体human umbilical cord mesenchymal stem cell-derived exosomehUC-MSC-derived exosomesumbilical cord MSC-derived exosomes
02
Targets
ENG (Integrin Beta 6)FXR (Farnesoid x-activated receptor)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)TGFB1 (Transforming growth factor Beta-1 proprotein)ACSL4 (Acyl-CoA synthetase long-chain family member 4)
Beyond the preview
Go deeper on human umbilical cord mesenchymal stem cell-derived exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on human umbilical cord mesenchymal stem cell-derived exosomes.